Active, not recruitingPhase 2NCT05540860

A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)

Studying Duchenne muscular dystrophy

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Edgewise Therapeutics, Inc.
Intervention
Sevasemten Dose 1(drug)
Enrollment
76 enrolled
Eligibility
4-9 years · MALE
Timeline
20222027

Study locations (14)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05540860 on ClinicalTrials.gov

Other trials for Duchenne muscular dystrophy

Additional recruiting or active studies for the same condition.

See all trials for Duchenne muscular dystrophy

← Back to all trials